Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dual target GD2/B7-H3 CAR-NK cell therapy - Beijing Biotech

Next Previous
Drug Profile

Dual target GD2/B7-H3 CAR-NK cell therapy - Beijing Biotech

Alternative Names: Dual target CAR-NK cell therapy - Beijing Biotech; EB-DTNB-NK - Beijing Biotech; GD2+B7-H3 (CD276) dual target CAR-NK cell therapy - Beijing Biotech

Latest Information Update: 20 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing BioTech
  • Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer; HER2 positive breast cancer; Neuroblastoma; Triple negative breast cancer

Most Recent Events

  • 02 Mar 2026 Phase-I/II clinical trials in Neuroblastoma (In infants, In children, In adolescents, In adults, Second-line therapy or greater) in China (IV) (NCT07502287)
  • 02 Feb 2026 Phase-I/II clinical trials in Breast cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT07510802)
  • 02 Feb 2026 Phase-I/II clinical trials in HER2-positive-breast-cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT07510802)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top